A small in number months ago, I wr...

A small in number months ago, I wrote a line on the rapid advancements in human genome technology and by what mode Wall Street was treating those advances like a luckles poker player treats a pair of aces forward the deal and two more forward the flop. In other words, true enthusiastically. It turns out that genomics is barely half the story. In Wall road brokerage firms, in financial advisor circles, and upon mutual fund trading desks, the other shoe has dropp in the form of the biochip--those DNA-styled microchips that more and more industry companies are starting to use to examine the genomic templates of